Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page

NIDA Home > About NIDA > Congressional and Legislative Activities > Medications Development Research for Treatment of Amphetamine and Methamphetamine Addiction - Report to Congress    

Medications Development Research for Treatment of Amphetamine and Methamphetamine Addiction - Report to Congress, August 2005

IV. Reference List

  1. Bell DS (1973) The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 29: 35-40.
  2. Brebner K, Ahn S, Phillips AG (2005) Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates. Psychopharmacology (Berl) 177: 409-417.
  3. Brunswick DJ, Benmansour S, Tejani-Butt SM, Hauptmann M (1992) Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Synapse 11: 287-293.
  4. Cadet JL, Jayanthi S, Deng X (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17: 1775-1788.
  5. Cass WA (2000) Attenuation and recovery of evoked overflow of striatal serotonin in rats treated with neurotoxic doses of methamphetamine. J Neurochem 74: 1079-1085.
  6. Cass WA, Manning MW (1999) Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 19: 7653-7660.
  7. Chang L, Ernst T, Speck O, Grob CS (2005) Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162: 361-369.
  8. Chang L, Smith LM, LoPresti C, Yonekura ML, Kuo J, Walot I, Ernst T (2004) Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res 132: 95-106.
  9. Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse, Vol. II, Proceedings of the Community Epidemiology Work Group. January 2005. NIH Pub. In Press. 2005.
  10. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274-5278.
  11. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I (2003) Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188: 1820-1826.
  12. Ellison G, Eison MS, Huberman HS, Daniel F (1978) Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 201: 276-278.
  13. Friedman SD, Castaneda E, Hodge GK (1998) Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61: 35-44.
  14. Fuller RW, Hemrick-Luecke S (1980) Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats. Science 209: 305-307.
  15. Gavrilin MA, Mathes LE, Podell M (2002) Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol 8: 240-249.
  16. Griffith, J. D., Cavanaugh, J., and Oates, J. Schizophreniform psychosis induced by large-dose administration of D-amphetamine. J.Psychedel.Drugs 2, 42-48. 1969.
  17. Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, Bardo MT (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther 298: 172-179.
  18. Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871: 259-270.
  19. Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, Horita N, Kaneko T (1994) Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr Scand 89: 428-432.
  20. Jayanthi S, Deng X, Bordelon M, McCoy MT, Cadet JL (2001) Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex. FASEB J 15: 1745-1752.
  21. Johnston, L. D., O'Malley, P. M., Bachman, J. G., and Schulenberg, J. E. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2004 (NIH Publication No. 05-5726). Bethesda, MD: National Institute on Drug Abuse. 2005.
  22. Kita T, Wagner GC, Nakashima T (2003) Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci 92: 178-195.
  23. Kono J, Miyata H, Ushijima S, Yanagita T, Miyasato K, Ikawa G, Hukui K (2001) Nicotine, alcohol, methamphetamine, and inhalant dependence: a comparison of clinical features with the use of a new clinical evaluation form. Alcohol 24: 99-106.
  24. Kramer JC, Fischman VS, Littlefield DC (1967) Amphetamine abuse. Pattern and effects of high doses taken intravenously. JAMA 201: 305-309.
  25. Li JX, Han R, Deng YP, Chen SQ, Liang JH (2005) Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice. Behav Brain Res 161: 125-132.
  26. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods R, Rawson R, Ling W (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61: 73-84.
  27. Melega WP, Lacan G, Desalles AA, Phelps ME (2000) Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey. Synapse 35: 243-249.
  28. Morbitity Mortality Weekly Report. Lead poisoning associated with intravenous methamphetamine use -- Oregon, 1988. 38[48], 830-831. 1989.
  29. Murray JB (1998) Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol 132: 227-237.
  30. Petry, N. M., Peirce, J. M., Stitzer M.L., Blaine, J., Roll J.M., Cohen, A., Obert, J., Killeen, T., Saladin, M. E., Cowell, M., Kirby, K. C., Sterling, R., Royer-Malvestuto, C., Hamilton, J., Booth, R. E., Macdonald, M., Liebert M., Rader, L., Burns, R., DiMaria, J., Copersino, M., Stabile, P. Q., Kolodner K., and Li, R. Prize-based incentives improve outcomes of stimulant abusers in outpatient psychosocial treatment programs: A national drug abuse treatment clinical trials network study. Arch.Gen.Psychiatry In press. 2005.
  31. Plessinger MA (1998) Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 25: 119-138.
  32. Ranaldi R, Poeggel K (2002) Baclofen decreases methamphetamine self-administration in rats. Neuroreport 13: 1107-1110.
  33. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J (2004) A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 99: 708-717.
  34. Ricaurte GA, Schuster CR, Seiden LS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193: 153-163.
  35. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, Wolfson T, Grant I (2004) Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10: 1-14.
  36. Sato M (1992) A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci 654: 160-170.
  37. Seiden LS, Commins DL, Vosmer G, Axt K, Marek G (1988) Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann N Y Acad Sci 537: 161-172.
  38. Shepard JD, Bossert JM, Liu SY, Shaham Y (2004) The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 55: 1082-1089.
  39. Smith, D. E. and Fischer, C. M. Acute amphetamine toxicity. J.Psychedel.Drugs 2, 49-54. 1969.
  40. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M (2003) Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 6: 347-352.
  41. Substance Abuse and Mental Health Administration, Office of Applied Studies. Emergency Department Trends from DAWN: Final Estimates 1995-2002. DAWN Series D-24 DHHS Pub.No.(SMA) 03-3780. Rockville, MD. 2003.
  42. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24: 6028-6036.
  43. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
  44. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler JS (2004) Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 161: 242-248.
  45. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS (1989) Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486: 73-78.
  46. Wouldes T, LaGasse L, Sheridan J, Lester B (2004) Maternal methamphetamine use during pregnancy and child outcome: what do we know? N Z Med J 117: U1180.
  47. Yui K, Goto K, Ikemoto S, Ishiguro T (2000) Stress induced spontaneous recurrence of methamphetamine psychosis: the relation between stressful experiences and sensitivity to stress. Drug Alcohol Depend 58: 67-75.

Medications Development Research for Treatment of Amphetamine and Methamphetamine Addiction - Report to Congress

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal